Of the included 13 799 patients with T2D and CKD stages 1 to 3, 12 331 (89.4%) received SGLT2 inhibitors (7548 men [61.2%] and 4783 women [38.8%]; mean [SD] age, 62.4 [12.3] years; median [IQR] HbA1c level, 8.4% [7.5%-9.7%]; median [IQR] eGFR, 69.0 [53.0-90.7] mL/min/1.73 m2; and median [IQR] UACR, 101.0 [38.5-316.5] mg/g), very similar to the GLP-1 RA group (1468 patients; 900 men [61.3%] and 568 women [38.7%]; mean [SD] age, 61.5 [13.3] years) after applying the study inclusion and exclusion criteria and propensity scores with fine stratification weights (Figure 1). The gene discussed is SLC5A2; the disease is chronic kidney disease.